Michael L. Jackson’s research focuses on understanding how infectious diseases spread, and on designing and evaluating interventions such as vaccination programs. Dr. Jackson is the Group Health Research Institute (GHRI) principal investigator for the United States Influenza Vaccine Effectiveness Network. This Network aims to provide ongoing evaluations of the U.S. influenza vaccination program. Dr. Jackson uses data from this Network to study influenza vaccine effectiveness, to estimate the burden of disease caused by influenza, and to advance the methodology of vaccine effectiveness studies. He also uses mathematical models to predict the impact of vaccination programs on the spread of infectious diseases such as Haemophilus influenza type b (Hib) and Neisseria meningitidis.
Dr. Jackson is a co-investigator on the Vaccine Safety Datalink (VSD) Project. The VSD, a collaboration among nine U.S. managed care organizations and the Centers for Disease Control and Prevention (CDC), is the world’s premier system for post-licensure studies of vaccine safety. As a VSD co-investigator, Dr. Jackson leads studies of the safety of childhood immunizations and develops methods for using managed care data for vaccine safety studies.
While studying for his PhD at the University of Washington, Dr. Jackson was a graduate research associate with GHRI from 2002 to 2007, and then a postdoctoral fellow at GHRI from 2007 to 2008. He then spent two years as an Epidemic Intelligence Service (EIS) officer with the CDC in Atlanta. As an EIS officer, Dr. Jackson helped lead investigations of whooping cough outbreaks and of the 2009 influenza pandemic. He also designed and oversaw an enhanced surveillance system for invasive Hib disease in the U.S. during the 2008–2009 shortage of Hib vaccines. He returned to GHRI as an assistant investigator in 2010.
Disease burden, risk factors, transmission dynamics, surveillance and response
Rates of adverse events, safety of new vaccines
Methodology, removing bias in effectiveness estimates
Jackson ML, Rothman KJ.Effects of imperfect test sensitivity and specificity on observational studies of influenza vaccine effectiveness.
Vaccine. 2015 Feb 7. pii: S0264-410X(15)00126-7. doi: 10.1016/j.vaccine.2015.01.069. [Epub ahead of print]. PubMed
Flannery B, Clippard J, Zimmerman RK, Nowalk MP, Jackson ML, Jackson LA, Monto AS, Petrie JG, McLean HQ, Belongia EA, Gaglani M, Berman L, Foust A, Sessions W, Thaker SN, Spencer S, Fry AM.Early estimates of seasonal influenza vaccine effectiveness - United States, January 2015.
MMWR Morb Mortal Wkly Rep. 2015;64(1):10-5. PubMed
Abrams JY, Weintraub ES, Baggs JM, McCarthy NL, Schonberger LB, Lee GM, Klein NP, Belongia EA, Jackson ML, Naleway AL, Nordin JD, Hambidge SJ, Belay ED.Childhood vaccines and Kawasaki disease, Vaccine Safety Datalink, 1996-2006.
Vaccine. 2015;33(2):382-7. doi: 10.1016/j.vaccine.2014.10.044. Epub 2014 Nov 4. PubMed
Jackson ML, Peterson D, Nelson JC, Greene SK, Jacobsen SJ, Belongia EA, Baxter R, Jackson LA.Using winter 2009-2010 to assess the accuracy of methods which estimate influenza-related morbidity and mortality.
Epidemiol Infect. 2014 Dec 12:1-9. [Epub ahead of print].
KPLU, January 15, 2015
Vaccines: Benefits outweigh the risks